EBITDA: Income before interest, taxes, depreciation and amortization.
Enanta Pharmaceuticals, Inc. (ENTA) had EBITDA of $-16.04M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$14.36M |
|
$-19.50M |
|
-- |
|
$14.36M |
|
$31.59M |
|
$-17.24M |
|
$-2.23M |
|
$-19.46M |
|
$-19.46M |
|
$-19.50M |
|
$-19.50M |
|
$-19.50M |
|
$-19.50M |
|
$-17.24M |
|
|
EBITDA |
$-16.04M |
29.09M |
|
29.09M |
|
$-0.67 |
|
$-0.67 |
|
| Balance Sheet Financials | |
$203.62M |
|
$31.94M |
|
$93.25M |
|
$296.87M |
|
$54.17M |
|
-- |
|
$141.64M |
|
$195.80M |
|
$101.07M |
|
$101.07M |
|
$101.07M |
|
29.12M |
|
| Cash Flow Statement Financials | |
$-28.83M |
|
$-21.35M |
|
$51.30M |
|
$35.66M |
|
$36.78M |
|
$1.12M |
|
$11.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-120.04% |
|
-120.04% |
|
-- |
|
-135.56% |
|
-135.81% |
|
$-28.99M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
2.20 |
|
40.95 |
|
-19.29% |
|
-19.29% |
|
-6.57% |
|
-19.29% |
|
$3.47 |
|
$-1.00 |
|
$-0.99 |
|